🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

Recruitingn/aAges 18 Years - anyAllMedical University of Vienna
NCT07150299 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging. In parallel, the six-minute walk test (6MWT) is an established clinical tool to assess submaximal exercise capacity in patients with structural heart disease. Despite its widespread use, the relationship between objective changes in myocardial perfusion and functional improvements assessed by the 6MWT remains insufficiently explored in patients with HOCM on optimal medical therapy (OMT). Aim:This study aims to evaluate whether changes in functional capacity, measured by the 6MWT, correlate with changes in myocardial perfusion reserve (MPR) in HOCM patients treated with OMT. Methods: We will include patients diagnosed with obstructive HCM who previously underwent clinically indicated CMR perfu

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age \> 18 years * Willingness to provide written informed consent * Diagnosis of obstructive HCM based on ESC 2023 criteria * Planned CMR with myccardial perfusion for clinical purposes * Receiving guideline-conform OMT * Ability and willingness to undergo follow-up imaging and testing * Written informed consent Exclusion Criteria: * Claustrophobia or other contraindication for CMR imaging * Significant coronary artery disease and/or prior stent implantation or coronary artery bypass graft surgery * History of sudden cardiac arrest or sustained ventricular arrhythmia 12 months prior to screening * Glomerular filtration rate \< 30ml/min/m2 * Significant hepatic impairment defined as 3x upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase; hepatic cirrhosis * Known allergy to contrast agent * Alternative disease causing hypertrophic cardiomyopathy (e.g. cardiac amyloidosis, Morbus Fabry) * Pregnant women (and women with childbearing potential with desire for pregnancy) * Breastfeeding women * Unwillingness to comply with the study protocol and its procedures
💊

What it tests

  • Mavacamten in clinical routine use
📍

Where

1 site
Medical University of Vienna
Vienna, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy